Overview
Edesa Biotech Inc Q3 loss per share narrows to $0.25 from $0.52 last year; net loss remains $1.7 mln
Loss from operations stable at $1.9 mln
Result Drivers
EB06 FOCUS - Increased expenditures on EB06 for vitiligo study offset by reduced EB05 expenses, supported by government funding
EXPENSE MANAGEMENT - Stable operating expenses reflect strategic resource allocation towards EB06 development
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 EPS | -$0.25 | ||
Q3 Net Income | -$1.7 mln | ||
Q3 loss from operations | $1.9 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Edesa Biotech Inc is $9.00, about 76.8% above its August 7 closing price of $2.09
Press Release: ID:nGNX4Svytt
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)